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Background
Adoptive transfer of T cell receptor (TCR) redirected
T cells has traditionally targeted shared tumor-specific
antigens restricted to common major histocompatibility
complexes with the rationale of treating a large popula-
tion of patients. Recently, tumor infiltrating lymphocytes
(TIL) specific for mutated tumor neo-antigens have
been shown to play a key role in the clinical response to
immunotherapy, suggesting a need for a more persona-
lized therapy. We have shown that anti-tumor reactivity
in melanoma principally resides within the CD8+PD-1+
TIL repertoire. Moreover, T cell clones ranking highly
in this subset were demonstrated to be tumor-reactive
and mutation-specific. Therefore, we hypothesized that
the augmented frequency of a T cell clonotype within
the CD8+PD-1+TIL could be an indication of tumor
antigen-driven clonal expansion, and thus could guide
the identification of tumor-reactive TCRs.
Methods
TCRB sequencing was used to identify the most dominant
clonotypes in the CD8+PD-1+ sorted TIL populations.
TCRA and TCRB pairs were identified by Adaptive Pair-
seq of unsorted melanoma and single cell PCR analysis of
sorted populations. Full length TCR pairs were recon-
structed based on IMGT database [http://www.imgt.org],
synthetized and cloned into expression vectors. Open
repertoire T cells were transduced with these TCRs and
were co-cultured with autologous tumor cell lines and
antigen presenting cells expressing tandem minigenes
encoding mutated tumor neo-antigens and/or pulsed with
corresponding mutated peptides. Tumor and mutation
reactivity was determined by IFN-g ELISA and 4-1BB up-
regulation by flow cytometry.
Results
In 12 melanomas we were able to identify a median
value of 217 (range 11-883) TCRA-TCRB pairs by
Adaptive Pairseq and 29 (range 9-43) pairs by single cell
PCR. For each tumor we reconstructed 7 (range 4-8)
TCRs that were ranking within the top 10 clonotypes of
the CD8+PD-1+ TIL. Specificity analysis of these recon-
structed pairs revealed that in each tumor at least 1 and
up to 7 TCRs were tumor reactive.
Conclusions
Our novel approach allows a rapid identification of TCRs
with potential anti-tumor activity. Our data in fact show
that high frequency T cell clonotypes within the CD8+
PD-1+ population of melanoma TIL are commonly
tumor-reactive, suggesting that the frequency of TCRB
clonotypes in CD8+PD-1+ TIL may be used to guide iden-
tification of tumor-reactive TCRs.
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